ArticleClinical epigenetics2016
DNA methylation at birth within the promoter of ANRIL predicts markers of cardiovascular risk at 9 years.
Article in Clinical epigenetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 56 citations in OpenAlex.
- Early life epigenetics and childhood outcomes: a scoping review.Pediatric research · 2025Article
- Long Non-coding RNA ANRIL and Its Role in the Development of Age-Related Diseases.Molecular neurobiology · 2024Review
- Diagnostic potential of lncRNAs-ANRIL and MIAT in the blood of patients with cerebral venous thrombosis.Current journal of neurology · 2024Article
- ANRIL: A Long Noncoding RNA in Age-related Diseases.Mini reviews in medicinal chemistry · 2024Review
- Cardiovascular correlates of epigenetic aging across the adult lifespan: a population-based study.GeroScience · 2023Article
- Differential Expression of LOXL1-AS1 in Coronary Heart Disease and its Regulatory Mechanism in ox-LDL-Induced Human Coronary Artery Endothelial Cell Pyroptosis.Cardiovascular drugs and therapy · 2023Article
- Perinatal Lead Exposure Promotes Sex-Specific Epigenetic Programming of Disease-Relevant Pathways in Mouse Heart.Toxics · 2023Article
- Human non-CpG methylation patterns display both tissue-specific and inter-individual differences suggestive of underlying function.Epigenetics · 2022Article
- Epigenetic regulation of bone mass.Best practice & research. Clinical endocrinology & metabolism · 2022Review
- The Role of ANRIL in Atherosclerosis.Disease markers · 2022Review
- Genetic and epigenetic associations of ANRIL with coronary artery disease and risk factors.BMC medical genomics · 2021Article
- Influence of Maternal Lifestyle and Diet on Perinatal DNA Methylation Signatures Associated With Childhood Arterial Stiffness at 8 to 9 Years.Hypertension (Dallas, Tex. : 1979) · 2021Article
- Serum Levels of lncRNA CCHE1 and TCF21 in Patients with Coronary Artery Disease and Their Clinical Significances.Disease markers · 2021Article
- The Emerging Role and Promise of Circular RNAs in Obesity and Related Metabolic Disorders.Cells · 2020Review
- Epigenetic Signaling and RNA Regulation in Cardiovascular Diseases.International journal of molecular sciences · 2020Review
- Retracted Article: Long noncoding RNA ANRIL protects cardiomyocytes against hypoxia/reoxygenation injury by sponging miR-195-5p and upregulating Bcl-2.RSC advances · 2019Article
- DNA methylation of antisense noncoding RNA in the INK locus (ANRIL) is associated with coronary artery disease in a Chinese population.Scientific reports · 2019Article
- The Role of Epigenetics in Placental Development and the Etiology of Preeclampsia.International journal of molecular sciences · 2019Review
- Observational
- Mechanisms of Antisense Transcription Initiation with Implications in Gene Expression, Genomic Integrity and Disease Pathogenesis.Non-coding RNA · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
aimsAntisense non-coding RNA in the INK4 locus (ANRIL) fixed genetic variants have consistently been linked with coronary heart disease (CHD) risk. We investigated relationships between perinatal ANRIL promoter DNA methylation and CHD risk markers in children aged 9 years. Genetic variants in the non-coding RNA ANRIL identify it as an important CHD risk locus. Increasing evidence suggests that the early life environment may act through epigenetic processes to influence later CHD risk markers such as increased arterial pulse wave velocity (PWV, a measure of arterial stiffness) blood pressure or heart rate. METHODS AND
resultsUsing pyrosequencing, ANRIL DNA methylation at nine CpG sites was measured in the umbilical cord from 144 children in a UK mother-offspring cohort and related to the descending aorta PWV measured by velocity-encoded phase contrast MRI at age 9 years. Perinatal methylation was not associated with child's later blood pressure, but higher methylation at CpG5 was associated with increased childhood PWV (β = 0.066 m/s/10 % methylation increase [95 % CI, 0.004 to 0.128], p = 0.037); 10 % decreases in methylation at CpG1 and CpG2 were associated with increased heart rate (CpG1 β = 1.93 [0.07 to 3.8] beats/min, p = 0.041; CpG2 β = 2.30 [0.18 to 4.41] beats/min, p = 0.033, accounting for potential confounding variables). The associations with perinatal ANRIL promoter methylation were independent of neighbouring fixed genetic variants.
conclusionsOur findings suggest developmental epigenetic regulation of ANRIL promoter methylation as a factor in later CHD risk in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.